APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Polycythemia Vera Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Polycythemia Vera Drug Industry Growth and Trends Forecast to 2032

Report ID 174027010126 December 2025102 pages

Choose your research edition.

Industry ResearchPolycythemia Vera Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Polycythemia Vera Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Polycythemia Vera Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Polycythemia Vera Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Polycythemia Vera Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Polycythemia Vera Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Polycythemia Vera Drug include ANP Technologies, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Gilead Sciences, Inc., Italfarmaco S.p.A., Karus Therapeutics Limited, miRagen Therapeutics, Inc. and Nerviano Medical Sciences S.r.l., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Polycythemia Vera Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Polycythemia Vera Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Polycythemia Vera Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Polycythemia Vera Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Polycythemia Vera Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Polycythemia Vera Drug Market by Company

ANP Technologies, Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Galena Biopharma, Inc.

Gilead Sciences, Inc.

Italfarmaco S.p.A.

Karus Therapeutics Limited

miRagen Therapeutics, Inc.

Nerviano Medical Sciences S.r.l.

PharmaEssentia Corporation

Novartis AG

Teva Pharmaceutical Industries Ltd.

Polycythemia Vera Drug Segment by Type

Idelalisib

Givinostat

Dasatinib

M-009

Others

Polycythemia Vera Drug Segment by Application

Clinic

Hospital

Others

Polycythemia Vera Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polycythemia Vera Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Polycythemia Vera Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polycythemia Vera Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Polycythemia Vera Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Polycythemia Vera Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Idelalisib Table 2. Major Company of Givinostat Table 3. Major Company of Dasatinib Table 4. Major Company of M-009 Table 5. Major Company of Others Table 6. Global Polycythemia Vera Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 8. Global Polycythemia Vera Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Polycythemia Vera Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Polycythemia Vera Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Polycythemia Vera Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Polycythemia Vera Drug Sales by Type (2027-2032) & (W Units) Table 13. Global Polycythemia Vera Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Polycythemia Vera Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Polycythemia Vera Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Polycythemia Vera Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 18. North America Polycythemia Vera Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 20. Europe Polycythemia Vera Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 22. Asia-Pacific Polycythemia Vera Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 24. Latin America Polycythemia Vera Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 26. Middle East and Africa Polycythemia Vera Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Polycythemia Vera Drug Industry Trends Table 28. Polycythemia Vera Drug Industry Drivers Table 29. Polycythemia Vera Drug Industry Opportunities and Challenges Table 30. Polycythemia Vera Drug Industry Restraints Table 31. Global Polycythemia Vera Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Polycythemia Vera Drug Revenue Market Share by Company (2021-2026) Table 33. Global Polycythemia Vera Drug Sales by Company (2021-2026) & (W Units) Table 34. Global Polycythemia Vera Drug Sales Share by Company (2021-2026) Table 35. Global Polycythemia Vera Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Polycythemia Vera Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Polycythemia Vera Drug Major Company Production Sites and Headquarters Table 38. Global Polycythemia Vera Drug Company, Product Type & Application Table 39. Global Polycythemia Vera Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Polycythemia Vera Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Polycythemia Vera Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Polycythemia Vera Drug Sales by Region (2021-2026) & (W Units) Table 44. Global Polycythemia Vera Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Polycythemia Vera Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Polycythemia Vera Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Polycythemia Vera Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Polycythemia Vera Drug Sales by Region (2027-2032) & (W Units) Table 49. Global Polycythemia Vera Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Polycythemia Vera Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Polycythemia Vera Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Polycythemia Vera Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Polycythemia Vera Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 55. Global Polycythemia Vera Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Polycythemia Vera Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Polycythemia Vera Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Polycythemia Vera Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Polycythemia Vera Drug Sales by Application (2027-2032) & (W Units) Table 60. Global Polycythemia Vera Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Polycythemia Vera Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Polycythemia Vera Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Polycythemia Vera Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 65. North America Polycythemia Vera Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 67. Europe Polycythemia Vera Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 69. Asia-Pacific Polycythemia Vera Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 71. Latin America Polycythemia Vera Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 73. Middle East and Africa Polycythemia Vera Drug Sales by Application (2021-2026) & (US$ Million) Table 74. ANP Technologies, Inc. Company Information Table 75. ANP Technologies, Inc. Business Overview Table 76. ANP Technologies, Inc. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. ANP Technologies, Inc. Polycythemia Vera Drug Product Portfolio Table 78. ANP Technologies, Inc. Recent Development Table 79. Bristol-Myers Squibb Company Company Information Table 80. Bristol-Myers Squibb Company Business Overview Table 81. Bristol-Myers Squibb Company Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Bristol-Myers Squibb Company Polycythemia Vera Drug Product Portfolio Table 83. Bristol-Myers Squibb Company Recent Development Table 84. F. Hoffmann-La Roche Ltd. Company Information Table 85. F. Hoffmann-La Roche Ltd. Business Overview Table 86. F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Product Portfolio Table 88. F. Hoffmann-La Roche Ltd. Recent Development Table 89. Galena Biopharma, Inc. Company Information Table 90. Galena Biopharma, Inc. Business Overview Table 91. Galena Biopharma, Inc. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Galena Biopharma, Inc. Polycythemia Vera Drug Product Portfolio Table 93. Galena Biopharma, Inc. Recent Development Table 94. Gilead Sciences, Inc. Company Information Table 95. Gilead Sciences, Inc. Business Overview Table 96. Gilead Sciences, Inc. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Gilead Sciences, Inc. Polycythemia Vera Drug Product Portfolio Table 98. Gilead Sciences, Inc. Recent Development Table 99. Italfarmaco S.p.A. Company Information Table 100. Italfarmaco S.p.A. Business Overview Table 101. Italfarmaco S.p.A. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Italfarmaco S.p.A. Polycythemia Vera Drug Product Portfolio Table 103. Italfarmaco S.p.A. Recent Development Table 104. Karus Therapeutics Limited Company Information Table 105. Karus Therapeutics Limited Business Overview Table 106. Karus Therapeutics Limited Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Karus Therapeutics Limited Polycythemia Vera Drug Product Portfolio Table 108. Karus Therapeutics Limited Recent Development Table 109. miRagen Therapeutics, Inc. Company Information Table 110. miRagen Therapeutics, Inc. Business Overview Table 111. miRagen Therapeutics, Inc. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. miRagen Therapeutics, Inc. Polycythemia Vera Drug Product Portfolio Table 113. miRagen Therapeutics, Inc. Recent Development Table 114. Nerviano Medical Sciences S.r.l. Company Information Table 115. Nerviano Medical Sciences S.r.l. Business Overview Table 116. Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Product Portfolio Table 118. Nerviano Medical Sciences S.r.l. Recent Development Table 119. PharmaEssentia Corporation Company Information Table 120. PharmaEssentia Corporation Business Overview Table 121. PharmaEssentia Corporation Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. PharmaEssentia Corporation Polycythemia Vera Drug Product Portfolio Table 123. PharmaEssentia Corporation Recent Development Table 124. Novartis AG Company Information Table 125. Novartis AG Business Overview Table 126. Novartis AG Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Novartis AG Polycythemia Vera Drug Product Portfolio Table 128. Novartis AG Recent Development Table 129. Teva Pharmaceutical Industries Ltd. Company Information Table 130. Teva Pharmaceutical Industries Ltd. Business Overview Table 131. Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Product Portfolio Table 133. Teva Pharmaceutical Industries Ltd. Recent Development Table 134. North America Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 135. North America Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 136. North America Polycythemia Vera Drug Sales Market Share by Country (2021-2026) Table 137. North America Polycythemia Vera Drug Sales Forecast by Country (2027-2032) & (W Units) Table 138. North America Polycythemia Vera Drug Sales Market Share Forecast by Country (2027-2032) Table 139. North America Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. North America Polycythemia Vera Drug Market Size by Country (2021-2026) & (US$ Million) Table 141. North America Polycythemia Vera Drug Market Share by Country (2021-2026) Table 142. North America Polycythemia Vera Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. North America Polycythemia Vera Drug Market Share Forecast by Country (2027-2032) Table 144. Europe Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 145. Europe Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 146. Europe Polycythemia Vera Drug Sales Market Share by Country (2021-2026) Table 147. Europe Polycythemia Vera Drug Sales Forecast by Country (2027-2032) & (W Units) Table 148. Europe Polycythemia Vera Drug Sales Market Share Forecast by Country (2027-2032) Table 149. Europe Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Europe Polycythemia Vera Drug Market Size by Country (2021-2026) & (US$ Million) Table 151. Europe Polycythemia Vera Drug Market Share by Country (2021-2026) Table 152. Europe Polycythemia Vera Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Europe Polycythemia Vera Drug Market Share Forecast by Country (2027-2032) Table 154. Asia-Pacific Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 155. Asia-Pacific Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 156. Asia-Pacific Polycythemia Vera Drug Sales Market Share by Country (2021-2026) Table 157. Asia-Pacific Polycythemia Vera Drug Sales Forecast by Country (2027-2032) & (W Units) Table 158. Asia-Pacific Polycythemia Vera Drug Sales Market Share Forecast by Country (2027-2032) Table 159. Asia-Pacific Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Asia-Pacific Polycythemia Vera Drug Market Size by Country (2021-2026) & (US$ Million) Table 161. Asia-Pacific Polycythemia Vera Drug Market Share by Country (2021-2026) Table 162. Asia-Pacific Polycythemia Vera Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Asia-Pacific Polycythemia Vera Drug Market Share Forecast by Country (2027-2032) Table 164. Latin America Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 165. Latin America Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 166. Latin America Polycythemia Vera Drug Sales Market Share by Country (2021-2026) Table 167. Latin America Polycythemia Vera Drug Sales Forecast by Country (2027-2032) & (W Units) Table 168. Latin America Polycythemia Vera Drug Sales Market Share Forecast by Country (2027-2032) Table 169. Latin America Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Latin America Polycythemia Vera Drug Market Size by Country (2021-2026) & (US$ Million) Table 171. Latin America Polycythemia Vera Drug Market Share by Country (2021-2026) Table 172. Latin America Polycythemia Vera Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Latin America Polycythemia Vera Drug Market Share Forecast by Country (2027-2032) Table 174. Middle East and Africa Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 175. Middle East and Africa Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 176. Middle East and Africa Polycythemia Vera Drug Sales Market Share by Country (2021-2026) Table 177. Middle East and Africa Polycythemia Vera Drug Sales Forecast by Country (2027-2032) & (W Units) Table 178. Middle East and Africa Polycythemia Vera Drug Sales Market Share Forecast by Country (2027-2032) Table 179. Middle East and Africa Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Middle East and Africa Polycythemia Vera Drug Market Size by Country (2021-2026) & (US$ Million) Table 181. Middle East and Africa Polycythemia Vera Drug Market Share by Country (2021-2026) Table 182. Middle East and Africa Polycythemia Vera Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Middle East and Africa Polycythemia Vera Drug Market Share Forecast by Country (2027-2032) Table 184. Key Raw Materials Table 185. Raw Materials Key Suppliers Table 186. Polycythemia Vera Drug Distributors List Table 187. Polycythemia Vera Drug Customers List Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources Table 191. Primary Sources List of Figures Figure 1. Polycythemia Vera Drug Image Figure 2. Global Polycythemia Vera Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Polycythemia Vera Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Polycythemia Vera Drug Sales (2021-2032) & (W Units) Figure 5. Idelalisib Image Figure 6. Global Idelalisib Sales YoY Growth (2021-2032) & (W Units) Figure 7. Givinostat Image Figure 8. Global Givinostat Sales YoY Growth (2021-2032) & (W Units) Figure 9. Dasatinib Image Figure 10. Global Dasatinib Sales YoY Growth (2021-2032) & (W Units) Figure 11. M-009 Image Figure 12. Global M-009 Sales YoY Growth (2021-2032) & (W Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 15. Global Polycythemia Vera Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Polycythemia Vera Drug Market Share by Type 2025 VS 2032 Figure 17. North America Polycythemia Vera Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Polycythemia Vera Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Polycythemia Vera Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Polycythemia Vera Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Polycythemia Vera Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Polycythemia Vera Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Polycythemia Vera Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Polycythemia Vera Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Polycythemia Vera Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Polycythemia Vera Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Polycythemia Vera Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 35. Global Polycythemia Vera Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Polycythemia Vera Drug Market Share by Application 2025 VS 2032 Figure 37. North America Polycythemia Vera Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Polycythemia Vera Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Polycythemia Vera Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Polycythemia Vera Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Polycythemia Vera Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Polycythemia Vera Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Polycythemia Vera Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Polycythemia Vera Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Polycythemia Vera Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Polycythemia Vera Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Polycythemia Vera Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 48. North America Polycythemia Vera Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Polycythemia Vera Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Polycythemia Vera Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. Europe Polycythemia Vera Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Polycythemia Vera Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Polycythemia Vera Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Asia-Pacific Polycythemia Vera Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Polycythemia Vera Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Polycythemia Vera Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Latin America Polycythemia Vera Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Polycythemia Vera Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Polycythemia Vera Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Middle East and Africa Polycythemia Vera Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Polycythemia Vera Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Polycythemia Vera Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Polycythemia Vera Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Polycythemia Vera Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Idelalisib
  • Givinostat
  • Dasatinib
  • M-009
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • ANP Technologies, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Karus Therapeutics Limited
  • miRagen Therapeutics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • PharmaEssentia Corporation
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Polycythemia Vera Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Polycythemia Vera Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Polycythemia Vera Drug Market by Type
  6. 1.3.1 Idelalisib
  7. 1.3.2 Givinostat
  8. 1.3.3 Dasatinib
  9. 1.3.4 M-009
  10. 1.3.5 Others
  11. 1.4 Global Polycythemia Vera Drug Market Size by Type
  12. 1.4.1 Global Polycythemia Vera Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Polycythemia Vera Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Polycythemia Vera Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Polycythemia Vera Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Polycythemia Vera Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Polycythemia Vera Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Polycythemia Vera Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Polycythemia Vera Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Polycythemia Vera Drug Industry Trends
  2. 2.2 Polycythemia Vera Drug Industry Drivers
  3. 2.3 Polycythemia Vera Drug Industry Opportunities and Challenges
  4. 2.4 Polycythemia Vera Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Polycythemia Vera Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Polycythemia Vera Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Polycythemia Vera Drug Price (2021-2026)
  4. 3.4 Global Polycythemia Vera Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Polycythemia Vera Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Polycythemia Vera Drug Company, Product Type & Application
  7. 3.7 Global Polycythemia Vera Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Polycythemia Vera Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Polycythemia Vera Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Polycythemia Vera Drug Tier 1, Tier 2, and Tier 3
4 Polycythemia Vera Drug Regional Status and Outlook
  1. 4.1 Global Polycythemia Vera Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Polycythemia Vera Drug Historic Market Size by Region
  3. 4.2.1 Global Polycythemia Vera Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Polycythemia Vera Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Polycythemia Vera Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Polycythemia Vera Drug Forecasted Market Size by Region
  7. 4.3.1 Global Polycythemia Vera Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Polycythemia Vera Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Polycythemia Vera Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Polycythemia Vera Drug by Application
  1. 5.1 Polycythemia Vera Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Polycythemia Vera Drug Market Size by Application
  6. 5.2.1 Global Polycythemia Vera Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Polycythemia Vera Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Polycythemia Vera Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Polycythemia Vera Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Polycythemia Vera Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Polycythemia Vera Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Polycythemia Vera Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Polycythemia Vera Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ANP Technologies, Inc.
  2. 6.1.1 ANP Technologies, Inc. Company Information
  3. 6.1.2 ANP Technologies, Inc. Business Overview
  4. 6.1.3 ANP Technologies, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ANP Technologies, Inc. Polycythemia Vera Drug Product Portfolio
  6. 6.1.5 ANP Technologies, Inc. Recent Developments
  7. 6.2 Bristol-Myers Squibb Company
  8. 6.2.1 Bristol-Myers Squibb Company Company Information
  9. 6.2.2 Bristol-Myers Squibb Company Business Overview
  10. 6.2.3 Bristol-Myers Squibb Company Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bristol-Myers Squibb Company Polycythemia Vera Drug Product Portfolio
  12. 6.2.5 Bristol-Myers Squibb Company Recent Developments
  13. 6.3 F. Hoffmann-La Roche Ltd.
  14. 6.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 6.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 6.3.3 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Product Portfolio
  18. 6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 6.4 Galena Biopharma, Inc.
  20. 6.4.1 Galena Biopharma, Inc. Company Information
  21. 6.4.2 Galena Biopharma, Inc. Business Overview
  22. 6.4.3 Galena Biopharma, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Galena Biopharma, Inc. Polycythemia Vera Drug Product Portfolio
  24. 6.4.5 Galena Biopharma, Inc. Recent Developments
  25. 6.5 Gilead Sciences, Inc.
  26. 6.5.1 Gilead Sciences, Inc. Company Information
  27. 6.5.2 Gilead Sciences, Inc. Business Overview
  28. 6.5.3 Gilead Sciences, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Gilead Sciences, Inc. Polycythemia Vera Drug Product Portfolio
  30. 6.5.5 Gilead Sciences, Inc. Recent Developments
  31. 6.6 Italfarmaco S.p.A.
  32. 6.6.1 Italfarmaco S.p.A. Company Information
  33. 6.6.2 Italfarmaco S.p.A. Business Overview
  34. 6.6.3 Italfarmaco S.p.A. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Italfarmaco S.p.A. Polycythemia Vera Drug Product Portfolio
  36. 6.6.5 Italfarmaco S.p.A. Recent Developments
  37. 6.7 Karus Therapeutics Limited
  38. 6.7.1 Karus Therapeutics Limited Company Information
  39. 6.7.2 Karus Therapeutics Limited Business Overview
  40. 6.7.3 Karus Therapeutics Limited Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Karus Therapeutics Limited Polycythemia Vera Drug Product Portfolio
  42. 6.7.5 Karus Therapeutics Limited Recent Developments
  43. 6.8 miRagen Therapeutics, Inc.
  44. 6.8.1 miRagen Therapeutics, Inc. Company Information
  45. 6.8.2 miRagen Therapeutics, Inc. Business Overview
  46. 6.8.3 miRagen Therapeutics, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 miRagen Therapeutics, Inc. Polycythemia Vera Drug Product Portfolio
  48. 6.8.5 miRagen Therapeutics, Inc. Recent Developments
  49. 6.9 Nerviano Medical Sciences S.r.l.
  50. 6.9.1 Nerviano Medical Sciences S.r.l. Company Information
  51. 6.9.2 Nerviano Medical Sciences S.r.l. Business Overview
  52. 6.9.3 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Product Portfolio
  54. 6.9.5 Nerviano Medical Sciences S.r.l. Recent Developments
  55. 6.10 PharmaEssentia Corporation
  56. 6.10.1 PharmaEssentia Corporation Company Information
  57. 6.10.2 PharmaEssentia Corporation Business Overview
  58. 6.10.3 PharmaEssentia Corporation Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 PharmaEssentia Corporation Polycythemia Vera Drug Product Portfolio
  60. 6.10.5 PharmaEssentia Corporation Recent Developments
  61. 6.11 Novartis AG
  62. 6.11.1 Novartis AG Company Information
  63. 6.11.2 Novartis AG Business Overview
  64. 6.11.3 Novartis AG Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novartis AG Polycythemia Vera Drug Product Portfolio
  66. 6.11.5 Novartis AG Recent Developments
  67. 6.12 Teva Pharmaceutical Industries Ltd.
  68. 6.12.1 Teva Pharmaceutical Industries Ltd. Company Information
  69. 6.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
  70. 6.12.3 Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Product Portfolio
  72. 6.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments
7 North America by Country
  1. 7.1 North America Polycythemia Vera Drug Sales by Country
  2. 7.1.1 North America Polycythemia Vera Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Polycythemia Vera Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Polycythemia Vera Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Polycythemia Vera Drug Market Size by Country
  6. 7.2.1 North America Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Polycythemia Vera Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Polycythemia Vera Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Polycythemia Vera Drug Sales by Country
  2. 8.1.1 Europe Polycythemia Vera Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Polycythemia Vera Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Polycythemia Vera Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Polycythemia Vera Drug Market Size by Country
  6. 8.2.1 Europe Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Polycythemia Vera Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Polycythemia Vera Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Polycythemia Vera Drug Sales by Country
  2. 9.1.1 Asia-Pacific Polycythemia Vera Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Polycythemia Vera Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Polycythemia Vera Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Polycythemia Vera Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Polycythemia Vera Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Polycythemia Vera Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Polycythemia Vera Drug Sales by Country
  2. 10.1.1 South America Polycythemia Vera Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Polycythemia Vera Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Polycythemia Vera Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Polycythemia Vera Drug Market Size by Country
  6. 10.2.1 South America Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Polycythemia Vera Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Polycythemia Vera Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Polycythemia Vera Drug Sales by Country
  2. 11.1.1 Middle East and Africa Polycythemia Vera Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Polycythemia Vera Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Polycythemia Vera Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Polycythemia Vera Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Polycythemia Vera Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Polycythemia Vera Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Polycythemia Vera Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Polycythemia Vera Drug Value Chain Analysis
  2. 12.1.1 Polycythemia Vera Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Polycythemia Vera Drug Production Mode & Process
  7. 12.2 Polycythemia Vera Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Polycythemia Vera Drug Distributors
  10. 12.2.3 Polycythemia Vera Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst